We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF

84 hedge funds and large institutions have $157M invested in iShares US Pharmaceuticals ETF in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 36 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

15,100% more call options, than puts

Call options by funds: $608K | Put options by funds: $4K

3% less funds holding

Funds holding: 8784 (-3)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

16.14% less ownership

Funds ownership: 94.92%78.78% (-16%)

20% less capital invested

Capital invested by funds: $197M → $157M (-$39.6M)

50% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 36

67% less funds holding in top 10

Funds holding in top 10: 31 (-2)

Holders
84
Holders Change
-3
Holders Change %
-3.45%
% of All Funds
2.24%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.03%
New
8
Increased
18
Reduced
36
Closed
9
Calls
$608K
Puts
$4K
Net Calls
+$604K
Net Calls Change
+$345K

IHE Hedge Fund Activity: Q3 2016 in Review

84 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2016, worth a combined $157M — down 20% from $197M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of IHE and 8 opened new positions — a net loss of 1 holder — while 36 trimmed existing stakes and 18 added.

The largest buyer was Jane Street, adding an estimated $2.54M. The largest seller was Morgan Stanley, cutting an estimated $15.6M.

  • 84 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2016, down from 87 in Q2 2016.
  • Funds reported $157M of iShares US Pharmaceuticals ETF stock for Q3 2016, down 20% quarter-over-quarter.
  • 8 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2016 and 9 closed out, a net change of -1 holder.
  • The largest iShares US Pharmaceuticals ETF buyer in Q3 2016 was Jane Street, an estimated $2.54M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q3 2016 was Morgan Stanley, an estimated $15.6M sold.

Based on aggregated 13F filings for Q3 2016.